肝硬化腹水患者血清CK18 FGF-21水平与食管静脉曲张破裂出血及肝功能分级间的关系

doi:10.3969/j.issn.1006-6233.2021.06.017

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1232 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the relationship of the expression levels of serum cytokeratin 18 (CK18) and fibroblast growth factor 21 (FGF-21) with bleeding from esophageal varices (EV) and liver function classification in patients with liver cirrhosis ascites. Methods: 245 patients with liver cirrhosis ascites were selected and their serum CK18 and FGF-21 levels were tested. Serum CK18 and FGF-21 levels of patients with different Chid-Pugh grades of liver function were compared, and correlation analysis was carried out. According to the presence or absence of bleeding from EV, the patients were divided into bleeding group and non-bleeding group. Factors affecting bleeding from EV were analyzed. Results: CK18 levels of patients with grade A, grade B, and grade C liver function increased in turn (P<0.05), while FGF-21 levels of patients with grade A, grade B, and grade C liver function decreased in turn (P<0.05). The grade of liver function was positively correlated with CK18 (P<0.05), and negatively correlated with FGF-21 (P<0.05). There were statistically significant differences between the bleeding group and the non-bleeding group in terms of EV degree, Chid-Pugh classification of liver function, CK18 and FGF-21 expression levels (P<0.05). Logistic analysis showed that Chid-Pugh classification of liver function and CK18 were risk factors for bleeding from EV (P<0.05), while FGF-21 was a protective factor (P<0.05). Conclusion: The expression levels of serum CK18 and FGF-21 in patients with liver cirrhosis ascites are closely related to bleeding from EV and liver function classification.

Key words： Liver cirrhosis ascites Cytokeratin 18 Fibroblast growth factor 21 Esophageal varices Varices bleeding Chid-Pugh classification

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.06.017 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I6/958

[1] Yao CK,Fung J,Chu NHS,et al.Dietary interventions in liver cirrhosis[J].Clin Gastroenterol,2018,52(8):663~673.
[2] Roerecke M,Vafaei A,Hasan OSM,et al.Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis[J].Am Gastroenterol,2019,114(10):1574~1586.
[3] Hu C,Zhao L,Tao J,et al.Protective role of melatonin in early-stage and end-stage liver cirrhosis[J].Cell Mol Med,2019,23(11):7151~7162.
[4] Haidari F,Hojhabrimanesh A,Helli B,et al.An energy-restricted high-protein diet supplemented with β-cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: a randomized controlled trial[J].Nutr Res,2020,73:15~26.
[5] Su X,Kong Y,Peng D.Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease[J].Clin Chim Acta,2019,498:30~37.
[6] 中国中西医结合学会消化疾病专业委员会.肝硬化腹水的中西医结合诊疗共识意见[J].中国中西医结合杂志,2011,31(9):1171~1174.
[7] 谢亮,王姝,严德辉,等.乙型肝炎肝硬化患者肝功能分级与过敏毒素C3a水平的相关性[J].实用医学杂志,2018,34(11):1771~1773.
[8] 陈诗慧,毛荣军,宋少英,等.非酒精性脂肪性肝病大鼠血清细胞因子CK18-M30及FGF21的表达及意义[J].广东医学,2018,39(13):1947~1950.
[9] 李伟,陶晖,曹云,等.M-CSF诱导人骨髓间充质干细胞分化为肝样细胞的分子机制[J].基因组学与应用生物学,2020,39(2):252~256.
[10] 程钢,黄邓高,梁颖.诱导多功能干细胞来源肝样细胞体内抗肝纤维化[J].中国组织工程研究,2019,23(9):1384~1389.
[11] Darweesh SK,AbdElAziz RA,Abd-ElFatah DS,et al.Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by fibroscan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients[J].Eur Gastroenterol Hepatol,2019,31(5):633~641.
[12] Zarei M,Barroso E,Palomer X,et al.Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease[J].Mol Metab,2018,8:117~131.
[13] Takahashi A,Abe K,Fujita M,et al.Simple resistance exercise decreases cytokeratin 18 and fibroblast growth factor 21 levels in patients with nonalcoholic fatty liver disease: a retrospective clinical study[J].Medicine (Baltimore),2020,99(22):e20399.
[14] Krautbauer S,Rein-Fischboeck L,Haberl EM,et al.Circulating fibroblast growth factor 21 in patients with liver cirrhosis[J].Clin Exp Med,2018,18(1):63~69.
[15] 丁鹏鹏,张文辉,路筝,等.肝硬化食管胃静脉曲张破裂出血急诊胃镜下止血治疗失败的危险因素分析[J].中华消化杂志,2020,40(6):410~413.